• Do pancreatic cancer and chronic pancreatitis share the same genetic risk factors? A PANcreatic Disease ReseArch (PANDoRA) consortium investigation.

      Campa, Daniele; Pastore, Manuela; Capurso, Gabriele; Hackert, Thilo; Di Leo, Milena; Izbicki, Jakob R; Khaw, Kay-Tee; Gioffreda, Domenica; Kupcinskas, Juozas; Pasquali, Claudio; Macinga, Peter; Kaaks, Rudolf; Stigliano, Serena; Peeters, Petra H; Key, Timothy J; Talar-Wojnarowska, Renata; Vodicka, Pavel; Valente, Roberto; Vashist, Yogesh K; Salvia, Roberto; Papaconstantinou, Ioannis; Shimizu, Yasuhiro; Valsuani, Chiara; Zambon, Carlo Federico; Gazouli, Maria; Valantiene, Irena; Niesen, Willem; Mohelnikova-Duchonova, Beatrice; Hara, Kazuo; Soucek, Pavel; Malecka-Panas, Ewa; Bueno-de-Mesquita, H B As; Johnson, Theron; Brenner, Herman; Tavano, Francesca; Fogar, Paola; Ito, Hidemi; Sperti, Cosimo; Butterbach, Katja; Latiano, Anna; Andriulli, Angelo; Cavestro, Giulia Martina; Busch, Olivier R C; Dijk, Frederike; Greenhalf, William; Matsuo, Keitaro; Lombardo, Carlo; Strobel, Oliver; König, Anna-Katharina; Cuk, Katarina; Strothmann, Hendrik; Katzke, Verena; Cantore, Maurizio; Mambrini, Andrea; Oliverius, Martin; Pezzilli, Raffaele; Landi, Stefano; Canzian, Federico (2018-01-15)
      Pancreatic ductal adenocarcinoma (PDAC) is a very aggressive tumor with a five-year survival of less than 6%. Chronic pancreatitis (CP), an inflammatory process in of the pancreas, is a strong risk factor for PDAC. Several genetic polymorphisms have been discovered as susceptibility loci for both CP and PDAC. Since CP and PDAC share a consistent number of epidemiologic risk factors, the aim of this study was to investigate whether specific CP risk loci also contribute to PDAC susceptibility. We selected five common SNPs (rs11988997, rs379742, rs10273639, rs2995271 and rs12688220) that were identified as susceptibility markers for CP and analyzed them in 2,914 PDAC cases, 356 CP cases and 5,596 controls retrospectively collected in the context of the international PANDoRA consortium. We found a weak association between the minor allele of the PRSS1-PRSS2-rs10273639 and an increased risk of developing PDAC (ORhomozygous  = 1.19, 95% CI 1.02-1.38, p = 0.023). Additionally all the SNPs confirmed statistically significant associations with risk of developing CP, the strongest being PRSS1-PRSS2-rs10273639 (ORheterozygous  = 0.51, 95% CI 0.39-0.67, p = 1.10 × 10-6 ) and MORC4-rs 12837024 (ORhomozygous  = 2.07 (1.55-2.77, ptrend  = 0.7 × 10-11 ). Taken together, the results from our study do not support variants rs11988997, rs379742, rs10273639, rs2995271 and rs12688220 as strong predictors of PDAC risk, but further support the role of these SNPs in CP susceptibility. Our study suggests that CP and PDAC probably do not share genetic susceptibility, at least in terms of high frequency variants.
    • Hepcidin levels and gastric cancer risk in the EPIC-EurGast study.

      Jakszyn, Paula; Fonseca-Nunes, Ana; Lujan-Barroso, Leila; Aranda, Núria; Tous, Mónica; Arija, Victoria; Cross, Amanda; Bueno-de-Mesquita, H B As; Weiderpass, Elisabete; Kühn, Tilman; Kaaks, Rudolf; Sjöberg, Klas; Ohlsson, Bodil; Tumino, Rosario; Palli, Domenico; Ricceri, Fulvio; Fasanelli, Francesca; Krogh, Vittorio; Mattiello, Amalia; Jenab, Mazda; Gunter, Marc; Perez-Cornago, Aurora; Khaw, Kay-Tee; Tjønneland, Anne; Olsen, Anja; Overvad, Kim; Trichopoulou, Antonia; Peppa, Eleni; Vasilopoulou, Effie; Boeing, Heiner; Sánchez-Cantalejo, Emilio; Huerta, José María; Dorronsoro, Miren; Barricarte, Aurelio; Quirós, José Maria; Peeters, Petra H; Agudo, Antonio (2017-09-01)
      Hepcidin is the main regulator of iron homeostasis and dysregulation of proteins involved in iron metabolism has been associated with tumorogenesis. However, to date, no epidemiological study has researched the association between hepcidin levels and gastric cancer risk. To further investigate the relationship between hepcidin levels and gastric cancer risk, we conducted a nested case-control study (EURGAST) within the multicentric European Prospective Investigation into Cancer and Nutrition study. The study included 456 primary incident gastric adenocarcinoma cases and 900 matched controls that occurred during an average of 11 years of follow-up. We measured serum levels of hepcidin-25, iron, ferritin, transferrin and C-reactive protein. Odds ratios (ORs) and 95% confidence intervals (CIs) for the risk of gastric cancer by hepcidin levels were estimated from multivariable conditional logistic regression models. Mediation effect of the ferritin levels on the hepcidin-gastric cancer pathway was also evaluated. After adjusting for relevant confounders, we observed a statistically significant inverse association between gastric cancer and hepcidin levels (OR 5 ng/l = 0.96, 95% CI = 0.93-0.99). No differences were found by tumor localization or histological type. In mediation analysis, we found that the direct effect of hepcidin only represents a nonsignificant 38% (95% CI: -69%, 91%). In summary, these data suggest that the inverse association of hepcidin levels and gastric cancer risk was mostly accounted by ferritin levels. Further investigation including repeated measures of hepcidin is needed to clarify their role in gastric carcinogenesis.